Article Text

Download PDFPDF
P138 Transient myeloproliferative disorder followed by acute biphenotypic leukaemia in a child with down syndrome
  1. Neaga Alexandra-Elena1,
  2. Blag Cristina1,2,
  3. Bota Madalina1,
  4. Popa Gheorghe1,2
  1. 1Paediatric Clinic Number 2, Emergency Hospital for Children, Cluj-Napoca, Romania
  2. 2’Iuliu Hatieganu’ University of Medicine and Pharmacy, Cluj-Napoca, Romania


Background and aims Children diagnosed with Down syndrome have a distinctive predisposition to develop acute myeloblastic leukaemia of Down syndrome (ML-DS). This disease is preceded by a transient neonatal preleukemic state known as transient myeloproliferative disorder (TMD) which can be clinically obvious or silent. This condition is considered to be a paradox in oncology because it regresses spontaneously three months after birth, with a 5 year survival rate of approximately 80%.

Methods We report a case of a 3 year old girl with Down syndrome who was monitored in our clinic since she was one month old.

Results The patient was born with a Down phenotype from a dizygotic twin pregnancy, with a healthy brother. At the age of 8 days she started to present pallor and splenomegaly. Leukocytosis and thrombocytopenia were present and the May-Grunwald-Giemsa stained smears revealed 78% blasts, the aspect suggesting an acute congenital leukaemia, probably megakarioblastic. The immunophenotyping confirmed this diagnosis. The patient was diagnosed with TMD and achieved spontaneous complete remission at the age of 8 weeks and was periodically monitored in our department. At the age of 3 years she was admitted to our hospital with bleeding gums, petechiae and splenomegaly. The peripheral blood count revealed 70% blasts, anaemia and thrombocytopenia. The bone marrow aspirate concluded that it was an acute mixed phenotype, myeloid and B-lymphoblastic leukaemia. The patient started therapy with the AML-BFM 2004 protocol, achieving complete remission after the first block of chemotherapy.

ConclutionS It is estimated that 20%–30% of the neonates with TMD will eventually develop ML-DS. The blasts are similar to those in TMD, with a megakarioblastic morphology. However, in our case, the blasts first had the typical morphology, but when the patient developed ML-DS blasts had both myeloblastic and lymphoblastic characteristics. TMD and ML-DS have distinctive features which make it an exceptional in vitro model for myeloid leukemogenesis.

  • acute myeloblastic leukaemia
  • transient myeloproliferative disorder
  • Down syndrome

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.